Suraj Muley is a Neurology physician affiliated with HonorHealth. OpenAlex indexes 51 publications with 2,051 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
240 W Thomas Rd
Suite 400
Phoenix, AZ 850134407
Telephone
602-406-6262Registry record last updated 21 Jan 2014.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CSL BehringProgram year202592 payments$72,278openpaymentsdata.cms.gov ↗
- Alexion Pharmaceuticals, Inc.Program year202553 payments$52,908openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202537 payments$52,386openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
48.8%Cholinesterase Inhibitor12.9%Pyridostigmine Bromide100%Part D≥36 patientsGabapentinoids12.8%Gabapentin81%Pregabalin19%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
41.4%Corticosteroid41.4%Prednisone100%Part D≥72 patientsCancer & immunology
5.6%Complement Inhibitor4.3%Ultomiris67%Soliris33%Part D<11 patientsNeonatal Fc Receptor Blocker1.3%Vyvgart100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment
Journal of the Neurological Sciences
2024 - Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice
Frontiers in Neurology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Tania Phillips, MD
HonorHealth
Erkut Borazanci, MD, MS
HonorHealth
Zain Khalpey, MD, MRCS
HonorHealth
Venkatesh Ramaiah, MD
HonorHealth
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”